December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Updated data on roxadustat in patients with lower-risk MDS from the open-label portion of an ongoing randomized, double-blind phase III study suggest that roxadustat reduces transfusion burden and enables transfusion independence.